Related Experiment Videos
Insights
Combined modality therapy, including chemotherapy and irradiation, shows promising survival rates for pediatric Hodgkin
Area of Science:
- Pediatric Oncology
- Radiation Oncology
- Clinical Medicine
Background:
- Hodgkin's disease in children and adolescents presents unique treatment challenges.
- Treatment strategies have evolved to improve outcomes while minimizing long-term side effects.
Purpose of the Study:
- To evaluate the efficacy and outcomes of different treatment modalities for pediatric Hodgkin's disease.
- To compare survival and relapse-free survival rates based on treatment approach and disease stage.
Main Methods:
- Retrospective analysis of 66 pediatric patients treated between 1970-1980.
- Stratification of patients based on age (prepubertal/postpubertal) and disease stage (IA, IIA, IIB-IVB).
- Comparison of outcomes for patients treated with involved-field irradiation, extended-field irradiation, and combined modality therapy (chemotherapy + irradiation).
Main Results:
- 100% survival at 4 years for Stage IA/IIA patients treated with combined modality.
- Relapse-free survival was 86% for Stage IA/IIA treated with combined modality versus 70% with irradiation alone.
- For Stage IIB-IVB patients, 5-year survival was 86% and relapse-free survival was 60% with combined modality.
Conclusions:
- Combined modality therapy offers significant survival advantages for pediatric Hodgkin's disease, particularly for higher-stage or high-risk patients.
- Chemotherapy failure appears to be a more common cause of relapse than insufficient radiation in combined modality treatment.
- Clinical staging and combined modality therapy may be advantageous, avoiding surgical complications like splenectomy, though hypothyroidism and growth disturbances remain potential concerns.
Abstract:
Between 1970 and 1980, 66 children or adolescents with Hodgkin's disease were treated at the Children's Hospital of Philadelphia. Since 1977, prepubertal patients and postpubertal patients with Stage IIA massive mediastinal disease or Stage IIB-IVB disease were clinically staged and treated with six courses of chemotherapy and 2000 rad involved-field irradiation. Postpubertal patients with Stage IA or IIA disease were staged pathologically and treated with 3600-4400 rad extended-field irradiation. At four years, actuarial survival in 27 patients with Stage IA or IIA disease is 100%; relapse-free survival is 86% in 16 patients treated with combined modality and 70% in 11 patients treated with irradiation. Among 39 patients with Stage IIB-IVB disease, 34 received combined modality; at five years, survival is 86% and relapse-free survival is 60%. In the majority of cases relapses in patients treated with combined modality could be better explained by chemotherapy failure rather than by insufficient radiation. Clinical staging and combined modality therapy may offer advantages for prepubertal patients and those postpubertal patients at high risk of relapse when treated with irradiation alone. The complications of laparotomy and splenectomy are avoided; however, with 2000 rad and limited-field irradiation, hypothyroidism does occur and growth disturbances may appear.